Simonetti R G, Craxi A, Dardanonì G, Lanzarone F, Barbaria F, Cottone M, Pagliaro L
Hepatogastroenterology. 1985 Dec;32(6):276-8.
Serum ferritin is often elevated in patients with hepatocellular carcinoma (HCC). Its use as a disease marker has been proposed. We have measured serum ferritin levels in 85 patients with HCC and in 62 comparable subjects with cirrhosis. Abnormal values (greater than or equal to 300 ng/ml) were found in 54% of the patients with HCC and in 35% of those with cirrhosis (median 323 and 204 ng/ml, respectively). The overlap of the range of concentration in HCC and cirrhosis was so great that no discriminant level could be chosen. No relationship was found between alpha-fetoprotein and ferritin concentrations. Among 61 patients who received Adriamycin treatment, no discernible fall in ferritin levels was observed, while alpha-fetoprotein increased progressively during the follow-up. Serum ferritin has no role in diagnosing and/or monitoring the response to treatment of patients with HCC.
肝细胞癌（HCC）患者的血清铁蛋白水平常升高。有人提议将其用作疾病标志物。我们检测了85例HCC患者和62例具有可比性的肝硬化患者的血清铁蛋白水平。HCC患者中有54%、肝硬化患者中有35%出现异常值（大于或等于300 ng/ml）（中位数分别为323和204 ng/ml）。HCC和肝硬化患者的血清铁蛋白浓度范围重叠很大，以至于无法选择鉴别水平。未发现甲胎蛋白与铁蛋白浓度之间存在关联。在61例接受阿霉素治疗的患者中，未观察到铁蛋白水平有明显下降，而在随访期间甲胎蛋白逐渐升高。血清铁蛋白在HCC患者的诊断和/或治疗反应监测中不起作用。
